Do pricing and usage-enhancing policies differ between biosimilars and generics? Findings from an international survey

Sabine Vogler, PhD; Peter Schneider, MA

Introduction/Study objective: This paper aims to survey the policies implemented by European countries for pricing and promoting the use of biosimilar medicines and to explore similarities and differences with policies for generic medicines.

Methods: A literature review was supplemented by primary data collection with policymakers. Members of the Pharmaceutical Pricing and Reimbursement Information (PPRI) network, a network of competent authorities for pharmaceutical pricing and reimbursement in 46 countries, responded to a survey in 2016.

Results: Information is available from 40 European countries, thereof 28 European Union Member States, as well as Canada and South Africa. We identified a common method for pricing generic (used in 30 countries) and biosimilar medicines (used in 15 countries) to set prices at a defined percentage beneath that of the originator price ('generic/biosimilar price link'). The required difference between originator and biosimilar medicine prices was lower than for generics in all but six of the countries. Tendering procedures are used for off-patent medicines in some countries, e.g. Denmark and The Netherlands – outpatient; Norway – inpatient, however, biosimilars have only recently been included in tenders. While generics substitution is in place in most surveyed countries, substituting a biosimilar medicine for an originator medicine at community pharmacy level is applied in only some countries, mainly in Central and Eastern Europe.

Discussion and conclusion: While pricing policies and instruments to enhance the uptake of generics are advanced, the surveyed countries appear to be struggling to find the most appropriate approach for biosimilar medicines.

Keywords: Biosimilar, generic, policy, pricing, substitution, tender

Introduction/Study objective

Public payers are concerned with ensuring patient access to medicines, particularly in the light of increasing pressure on budgets and the market entry of new, high-priced medicines [1]. One opportunity to generate savings and thus free resources for further investments in health is increased uptake of lower-priced medicines, such as generics. The use of generic medicines has been recommended by the World Health Organization (WHO) [2] and policymakers employ a range of supply- and demand-side tools to increase their uptake. These include generics substitution, physicians prescribing by the International Nonproprietary Name (INN) rather than the brand name, a reference price system, i.e. fixed reimbursement within a cluster of identical and similar medicines, and awareness-raising campaigns [3-9]. The ability of generics-promoting policies to reduce medicine prices and generate savings for health care has been well documented [10, 11].

Since biological medicines also significantly contribute to the pharmaceutical bill, policymakers are awaiting the entry of biosimilar medicines [12, 13], which are expected to generate substantial savings [14]. Recent years have seen several examples of tendering for biosimilar medicines successfully reducing prices [15, 16].

Under the Platform on Access to Medicines in Europe of the Corporate Social Responsibility Process, a multi-stakeholder working group was dedicated to biosimilar medicines. The working group produced a European Commission Consensus Information Document agreed by all stakeholders represented, the document provided key information about biosimilar medicines in order to foster stakeholders’ understanding of biosimilars [17]. However, the working group did not investigate which pricing and usage-enhancing policies European Union Member States applied for biosimilar medicines.

While there is good evidence of the implementation of pricing and demand-side measures for generics in Europe [3-11], the policies that European countries have been implementing to deal with biosimilar medicines are comparatively less known. To the best of the authors’ knowledge, there are few studies in the literature that provide information about pricing and demand-side policies for biosimilar medicines and the only comparative exercise performed across a large number of countries was published by the European Biopharmaceutical Enterprises in 2015 [18]. While the authors recognize the importance of this study, it did not fully explore all aspects of biosimilar medicines policies. Further studies that investigate biosimilar medicines policies are limited to a few countries [19-21] and/or to a single policy [22]. Furthermore, the findings of these studies differ.

Against this backdrop, this manuscript aims to survey the pricing and usage-enhanced policies that different countries, in particular in the European region, have implemented for biosimilar medicines, and to explore whether these policies differ from generic medicines policies.

Author for correspondence: Sabine Vogler, PhD, Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Head of Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG/Austrian Public Health Institute), 6 Stubenring, AT-1010 Vienna, Austria

Submitted: 30 March 2017; Revised: 26 May 2017; Accepted: 26 May 2017; Published online first: 9 June 2017
Methods

We conducted a survey with the members of the Pharmaceutical Pricing and Reimbursement Information (PPRI) network [23]. This is a network of competent authorities for pharmaceutical pricing and reimbursement in 46 countries, thereof 43 European countries. It should be noted that European countries are those as defined by WHO [24], and thus include countries such as Israel, Kazakhstan and Kyrgyzstan.

We prepared questions about the status of generic and biosimilar medicines policies. We explored the pricing policies for generics and biosimilars, in particular regarding possible regulation linking the generic and/or biosimilar price to the originator price. We surveyed whether INN prescribing and substitution by generic and biosimilar medicines was permitted, and whether it was mandatory. We also aimed to identify further specific pricing policies, e.g. tendering.

While the focus of this survey was on policies for biosimilar medicines, we also aimed to survey, or validate, information on generic medicines policies in order to explore possible differences between policies for the two medicine groups.

As far as possible, we pre-filled the questionnaire with information available to us, through previous research and literature review. This was predominantly only possible in the field of generics. Respondents from the competent authorities were invited to provide, or validate, information on biosimilar and generic medicines policies valid in the first quarter of 2016.

We sent the survey to the PPRI network members on 7 January 2016, requesting their responses by 19 January 2016. A friendly reminder was sent before the deadline, and a further personalized reminder that was focused on key questions was sent on 11 February 2016. Preliminary results were presented and discussed during a meeting with PPRI network members on 28 April 2016, where any misunderstandings could be clarified. In response to this discussion, we created a revised version of the questionnaire, which was circulated for validation on 30 May 2016. During the survey, respondents were encouraged to reply and clarification was sought in the case of answers that raised additional questions. On 1 August 2016, the survey was officially closed and the results were shared with participants. An uncompleted version of the revised questionnaire, i.e. without pre-filled answers, is available in the Annex.

While this survey with the PPRI network was the key survey tool, where considered appropriate we added relevant information from the literature (indicated by references).

Results

Response rate

We received responses from 36 of the 43 European PPRI members, as well as Canada and South Africa. Replies from the European region were provided by 25 of the 28 EU Member States (no data received from Ireland, Italy and Luxembourg) plus Albania, Belarus, Iceland, Israel, Kazakhstan, Kyrgyzstan,
Norway, Russia, Serbia, Turkey and Ukraine. Data from the missing three EU Member States and Switzerland were added, whenever possible, from literature and previous PPRI network queries on related topics. As a result, this manuscript includes information from 40 European countries, Canada and South Africa.

Pricing policies

Several countries apply a pricing policy that sets the price of follower products in relation to the price of the originator medicine. For generics, this is called ‘generic price link’. It is a commonly used practice that is applied in 30 of the 42 surveyed countries. Fifteen countries reported that they also apply such a strategy for biosimilar medicines. These are Austria, the Baltic States, Croatia, the Czech Republic, France, Iceland, Italy, Kazakhstan, Norway, Portugal, Romania, Slovakia and South Africa. Four ‘generic price link’ countries (Belgium, Bulgaria, Finland and Turkey) informed us that they do not apply a price-link policy for biosimilars. A further 10 European countries and Canada apply a generic price link but did not report whether they also use this policy for pricing biosimilar medicines.

In most of the countries that apply a generic and biosimilar price link, the price difference between the originator medicine and the biosimilar is, sometimes considerably, lower than that between originator and generic medicine. This implies that biosimilar medicines tend to have higher prices. For instance, in the Czech Republic the first generic drug must be priced 32% below that of the originator, whereas the price of the first biosimilar must only be 15% lower than the originator. Six countries (Austria, Iceland, Italy, Kazakhstan, Latvia and South Africa) apply the same price link for generic and biosimilar medicines. However, the design of this link is heterogeneous. In Italy for example, a Decree was passed that treats generics and biosimilars in the same way in the procedure of reimbursement. Both can automatically be reimbursable and classify for the same reference group as their originator, if the price proposed by the respective marketing authorization holder is favourable to the Italian Health Service. Austria (at the time of the survey, for information on further developments see the Discussion paragraph) and Latvia, on the contrary, have defined a percentage threshold under which the first follower – either generic or biosimilar – must be priced (48% and 30%, respectively), and percentage rates of how much the prices of further ‘followers’ must be lower than of previous generics or biosimilars. In Iceland, the price link is calculated based on the maximum wholesale price allowed for generic and biosimilar medicines. Figures 1 and 2 describe price-link policies for biosimilars and generics, including price differences.

Some countries in the survey described the use of tendering to procure biosimilars. Iceland and the UK for instance have been tendering for medicines, including biosimilars, in the inpatient sector. In Denmark, all medicines (including biosimilars) for the inpatient sector are procured by a national procurement agency (AMGROS) which is owned by the five ‘health regions’ [25]. The

Figure 2: Price-link policies for generic and biosimilar medicines in 40 European countries, Canada and South Africa

<table>
<thead>
<tr>
<th>Country</th>
<th>Generics</th>
<th>Biosimilars</th>
</tr>
</thead>
<tbody>
<tr>
<td>CZ</td>
<td>32%</td>
<td>15%</td>
</tr>
<tr>
<td>EE</td>
<td>30%</td>
<td>15%</td>
</tr>
<tr>
<td>FR</td>
<td>60%</td>
<td>10–30%</td>
</tr>
<tr>
<td>HR</td>
<td>30%</td>
<td>15%</td>
</tr>
<tr>
<td>LT</td>
<td>50%</td>
<td>30%</td>
</tr>
<tr>
<td>NO</td>
<td>Different calculation methods</td>
<td></td>
</tr>
<tr>
<td>PT</td>
<td>30–50%</td>
<td>20%</td>
</tr>
<tr>
<td>RO</td>
<td>35%</td>
<td>20%</td>
</tr>
<tr>
<td>SK</td>
<td>35%</td>
<td>20%</td>
</tr>
</tbody>
</table>

KZ, ZA: same price link to originator for generics and biosimilars. CA, IL, KG: not relevant/no information available.
Norwegian Drug Procurement Cooperation is responsible for purchasing medicines for public hospitals through annual tender processes. To ensure the acceptance of the awarded products, the results of the tender process and recommendations are presented by an expert group to affected stakeholders (industry, patient organizations, doctors) [26]. A similar approach is applied in Italy, however, in a decentralized manner; 20 Italian Regional Health Authorities (RHA) are responsible for planning healthcare services and allocating financial resources. All RHAs have established an organization for purchasing goods and services and two of them (Emilia-Romagna and Tuscany) additionally appointed a separate authority for procuring medicines. Various tenders for off-patent biologicals are conducted at regional levels [27]. In Spain, a pilot project of centralized procurement was reported to have taken place for the glycoprotein hormone and anaemia treatment erythropoietin (EPO).

Tendering in the outpatient sector is particularly used to procure for ‘public functions’, e.g. vaccines, centralized procurement in emergency situations such as pandemics [28]. Cyprus and Malta, both countries in which pharmaceutical services are provided separately by a public and a private sector, procure medicines (including biosimilars) for the public sector through tendering [29-31]. Some European countries have introduced tenders or tender-like systems in the outpatient sector; public payers launch tender calls for medicines that have generic (same active ingredient) or therapeutic alternatives. The lowest bidder will be either awarded the contract to supply the whole market or will be granted a preferential position on the reimbursement list, e.g. through higher coverage. Such a policy is applied in The Netherlands, where through the ‘preferential pricing policy’ health insurers tender for the lowest-priced off-patent medicine [28, 32, 33]. However, biosimilar medicines were only recently included in the tenders, and only by a limited number of insurers [25]. A tender-like procedure is also applied in the Danish off-patent outpatient market, which also includes biosimilar medicines. In their system, pharmaceutical companies submit bi-monthly price bids and the lowest-priced medicines are selected for full reimbursement within a two-week period [25, 33-36].

**Demand-side measures to encourage biosimilar uptake**

Prescribing by INN is a measure enforced by doctors that supports the uptake of generics as well as biosimilars. INN prescribing is in place in 35 European countries, Canada and South Africa, and is mandatory in 14 of the surveyed countries. It is only in Austria, Denmark, Serbia and Sweden that prescription by INN is not permitted, see Figure 3.

Another key demand-side measure to enhance the uptake of off-patent medicines is to allow community pharmacists to substitute the originator medicine with an off-patent medicine. Generics substitution is a commonly used practice. It is applied in 37 of the 42 countries (it is not permitted in Austria, Bulgaria, Denmark, Luxembourg and Serbia), and mandatory in

---

**Figure 3: Prescribing by International Nonproprietary Name in 40 European countries, Canada and South Africa**

- **Yes, mandatory**
- **Yes, indicative**
- **Not allowed**
- **Not in scope of the survey, and/or no information available**

CA, IL, KZ: yes, indicative; KG, ZA: yes, mandatory.
In 15 countries. In contrast, substitution of biosimilar medicines is only in place in some, mainly Central and Eastern European countries: Belarus, Cyprus, Czech Republic, Estonia, France, Iceland, Israel, Kazakhstan, Latvia, Malta, The Netherlands, Poland, Russia, Slovakia, Slovenia and Turkey. In some countries, e.g. Latvia, the substitution of an originator medicine by a biosimilar has not been explicitly implemented, but INN prescribing is obligatory and the medicine of the lowest price must be dispensed in the pharmacy, e.g. Latvia. There is usually no specific legal basis for biosimilar substitution; no law explicitly prohibited biosimilar substitution. In France, biosimilar substitution was introduced by the Social Insurance Law at the beginning of 2014 but is not yet in practice. Other countries reported opposition to biosimilar substitution by some stakeholders. In the Czech Republic for example, the Chamber of Pharmacists recommended against biosimilar substitution.

Discussion
Pricing and reimbursement policies for biosimilar medicines, as for generics, are embedded in the overall pricing and reimbursement framework. Policies for biosimilar medicines might be expected to be similar to those for generics, yet our survey showed that this is the case for only some policies and varies by country.

With regard to pricing of generic and biosimilar medicines, there are, in principle, two different approaches: to allow free pricing for off-patent medicines, and to allow for competition. The incentive for pharmaceutical manufacturers to offer low prices is to achieve higher market shares, since the lowest-priced medicines are likely to obtain more public funding and/or be recommended to pharmacists, doctors and patients. Reimbursement strategies, such as a reference price system or tendering for off-patent medicines, likely support competition.

An alternative policy is price regulation, typically in the form of a price link, whereby the price of a generic or biosimilar medicine is determined in relation to the originator price. This pricing policy appears to be commonly applied for generic medicines, even in combination with external price referencing (international price comparison) in several countries including Belgium, Hungary, Poland and Spain. In some countries, a price-link policy is applied for biosimilars as well. All countries that apply the price-link policy for biosimilar medicines do the same for generics. The survey showed, however, that several countries with a price-link policy for generics do not have one for biosimilar medicines. While four generic price link countries explicitly advised that they do not apply a price link for biosimilars, other countries with a generic price-link policy did not respond to the question about the use of price linkage for biosimilars. This suggests that legislation on this issue has not yet been decided, likely due to the novelty of the topic.

In 2016, a few countries, e.g. Austria, South Africa, did not apply specific pricing regulation for biosimilar medicines. They used...
the same procedures for all off-patent medicines, whether or not these medicines were generics or biosimilars (in Austria, for instance, legislation valid at the time of the survey referred only to ‘follower products’). Furthermore, the required price difference between the originator and follower medicine did not distinguish between biosimilars and generics in these countries. In most countries, however, the price difference was lower for the originator-biosimilar pair compared to the originator-generic pair. This indicates that competent authorities in these countries grant comparatively higher prices to biosimilar medicines.

Few large-scale price comparisons include biosimilar medicines, and therefore information about the impact of the two approaches for pricing biosimilars (price link versus competition) is not available. For generics, an illustrative study of selected active ingredients [37] showed that countries that base their pricing policy for generic medicines on competition tend to have a larger price difference between the originator and the generic medicine, and generics prices are often (but not consistently) lower [7, 38-41].

Overall, tendering appears to be an effective instrument to generate savings for public payers. Norway for example, reported huge discounts for biosimilar infliximab (minus 72% in 2015) [26]. Research into biosimilar tenders by regions of Italy revealed that for 191 analyzed lots referring to three off-patent biologicals (somatropin, epoetin and filgrastim) mentioned in 24 tenders performed between 2008 and 2012, the price of filgrastim and epoetin dropped considerably, whereas the price of somatropin remained steady. Somatropin had the lowest mean number of competitors (1.16), while filgrastim had the highest (2.75) [16]. Both Norway and Italy applied tenders targeted at biological and biosimilar medicines in the hospital sector. This is in line with the results of the EBE study on pricing and reimbursement policies for biological medicines, which showed that, while biological medicines are subject to tenders in several European countries, these are hospital tenders in the majority of cases [18].

Despite evidence of its effectiveness, tendering has rarely been applied for biosimilar medicines in the outpatient sector. Dutch health insurers are experienced in tendering for off-patent medicines but have traditionally refrained from including biosimilars in their tenders [42, 43]. Only recently have some Dutch insurers started launching tenders for biosimilars [25]. According to Dutch respondents, this is to be seen in the light of physician reluctance towards biosimilar medicines; while switching from the originator to a biosimilar medicine is allowed and would be appreciated by the competent authorities, it is not yet common practice.

However, pricing is only one aspect of encouraging generics and biosimilars use. Policies are also required that ensure the use of lower-priced medicines instead of higher-priced originator medicines. It is of key importance that patients trust generics and biosimilars; otherwise, they will insist on receiving the originator medicines even if they must pay more. Health professionals such as doctors and pharmacists play a key role in this respect, as their contributions in some countries such as Germany and Norway have shown [15, 44]. Health professionals must themselves understand the value of generics and biosimilars in order to communicate it to the patients. Thus, education and possibly incentives for health professionals are needed [45].

Much debate has centred around interchangeability and switching from originator medicines to biosimilars. Recent studies have been launched to prove the safety of switches [46], such as the NOR-SWITCH study, whose preliminary results suggest that a switch from originator infliximab to biosimilar infliximab is safe [47].

The Australian government announced in early 2015 that biosimilar medicines can be substituted by pharmacists based on the clinical recommendations of the Pharmaceutical Benefits Advisory Committee. The same rules that apply to generics also hold for biosimilars, and pharmacists are permitted to substitute any biosimilar medicine for an originator product, in the absence of clinical evidence to the contrary [48]. In Europe, however, biosimilar substitution has not been widely implemented, despite advanced generic medicines substitution. Countries that allow biosimilar substitution (or, at least, do not explicitly prohibit it) have been confronted with opposition by pharmacists and doctors.

It is important to note the limitations to this survey study. It concerns a new area for which data are scarce, and knowledge is limited. Since in many cases the literature does not provide conclusive information, we used primary data from members of the PPRI network, who are experts in the field of pharmaceutical pricing and reimbursement. However, we experienced a lower response rate to some of the specific questions related to biosimilar medicines. This could be a reflection of the novelty of the area for which specific policies are yet to be defined. Due to the novelty of the topic, terminology was not fully clear to all respondents, e.g. the distinction between switching by doctors and substitution by pharmacists. We addressed these challenges by providing definitions, arranging a debate of preliminary findings during a face-to-face meeting and organizing a second round of the survey based on a slightly revised questionnaire. We also aimed to validate responses using the literature, although this was not possible in several cases due to a lack of information or contradictions between sources, e.g. information on biosimilar substitution. This makes it difficult for us to discuss our findings in the light of existing literature. Further, our findings are not comprehensive. For instance, we did not survey the ‘switch climate’ or regulations for switches in different countries, as we felt that existing research had already covered these areas. The findings refer to the situation at the time of the survey (Spring 2016); in the meantime, changes in legislation might have occurred (as with the price-link policy in Austria, for instance, when in April 2017 different percentage rates for the price difference of the originator-biosimilar pair and of the originator-generic pair were introduced). Finally, this research is descriptive, and does not assess the possible impacts of policies on biosimilar prices or uptake.

Despite these limitations, we believe that our study provides interesting and updated results. Apart from the EBE study published in the same journal [18], this is the sole recent study that considers biosimilar and generic medicines policies across a large number of countries, including several non-European nations. The study also provides value by surveying both generic and biosimilar medicines, allowing a comparison between these two groups of medicines. Such a comparison has not been provided by past studies, including the above-mentioned [18], which only focused on biological and biosimilar medicines. The broad focus of our study (generic and biosimilar medicines policies)
offers novel information. Due to the novelty of the topic, it is
difficult to compare our findings with those of other research.

Conclusion
This study provides information about pricing policies and
demand-side measures to enhance the uptake of biosimilar
medicines for over 40 countries and compares them to practices
applied for generics. Some aspects surveyed here have not been
previously discussed in the literature.

Overall, the study shows that European countries have made
good use of available policies for pricing generics and enhancing
their uptake. However, with regard to biosimilar medicines,
policymakers in several countries appear to be struggling to
identify the most appropriate approach. Indeed, in many coun-
tries, pricing and usage-enhancing policies for biosimilars have
not yet been defined. Policymakers do not always apply instru-
ments that have been successfully implemented for generics to
biosimilar medicines. The reluctance to do so might result from
opposition to biosimilar medicines expressed by some stake-
holder groups, such as physicians.

There is a need for further research to investigate the possible
impacts of biosimilar medicines policies on prices, uptake and
expenditure. Given the ongoing development of policies for
biosimilar medicines, such studies need to be designed with a
long-term perspective. Descriptive surveys, such as this manu-
script, on policies and practices will help to inform such impact
assessments.

For patients
Biosimilar medicines have the potential to increase patient
access to medicines. Their prices are lower than those of origi-
nator medicines, which help to make biological medicines more
affordable. Biosimilar medicines contribute to reduced pharma-
daceutical expenditure and thus free financial resources, ultimately
allowing a greater number of patients to be treated. Policymak-
ers are called upon to introduce policies for the pricing, funding
and promotion of biosimilar medicines in order to take advan-
tage of these benefits. However, successful implementation of
pharmaceutical policies related to biosimilar medicines, as
described in this article, requires patients’ understanding and
acceptance. This research aims to contribute to patient knowl-
edge in this area.

Country abbreviations
AL: Albania; AT: Austria; BE, Belgium; BG: Bulgaria; BY: Belarus;
CA: Canada; CH: Switzerland; CY: Cyprus; CZ: Czech Republic;
DE: Germany; DK: Denmark; EE: Estonia; EL: Greece; ES: Spain;
FI: Finland; FR: France; HR: Croatia; HU: Hungary; IE: Ireland;
IL: Israel; IS: Iceland; IT: Italy; KG: Kyrgyzstan; KZ: Kazakhstan;
LT: Lithuania; LU: Luxembourg; LV: Latvia; MT: Malta; NL: The
Netherlands; NO: Norway; PL: Poland; PT: Portugal; RS: Republic
of Serbia; RU: Russia; RO: Romania; SE: Sweden; SI: Slovenia;
SK: Slovakia; TR: Turkey; UA: Ukraine; UK: United Kingdom; ZA:
South Africa.

Acknowledgements
Contributors: The authors thank their colleagues Ms Nina
Zimmermann and Ms Margit Gombocz in the Pharmaceutical
Pricing and Reimbursement Information (PPRI) Secretariat for
their support in the data collection of the survey. Furthermore,
we gratefully acknowledge the answers to the survey provided by
PPRI network members.

Funders: No funding was received for writing this manuscript.
The Austrian Federal Ministry of Health and Women’s Affairs
financially supports the Pharmaceutical Pricing and Reimburse-
ment Information (PPRI) Secretariat.

Prior presentations: Preliminary results related to one aspect
of the presented research (pricing policies for biosimilar medi-
cines) were presented at the ISPOR 19th Annual European
Congress in Vienna, Austria, 31 October – 2 November 2016.

Funding source: The authors gratefully acknowledge the support
of the Austrian Federal Ministry of Health and Women’s Affairs
to the Austrian Public Health Institute for running the PPRI
(Pharmaceutical Pricing and Reimbursement Information)
Secretariat that is managed by the authors and colleagues. The
members of the PPRI network (competent authorities for phar-
maceutical pricing and reimbursement) supported this research
by providing data and information for this manuscript. No fund-
ing for writing this manuscript was received.

Competing interests: None.

Provenance and peer review: Not commissioned; externally peer
reviewed.

Authors
Sabine Vogler, PhD; Peter Schneider, MA
WHO Collaborating Centre for Pharmaceutical Pricing and Reim-
bursement Policies, Pharmacoeconomics Department, Gesund-
heit Österreich GmbH (GÖG/Austrian Public Health Institute),
6 Stuhbenring, AT-1010 Vienna, Austria.

References
policies in public pharmaceutical spending in the EU. Economics and Financial
Affairs, 2012 [homepage on the Internet]. [cited 2017 May 26]. Available from:
pdf/ecp_461_en.pdf
2. World Health Organization. WHO Guideline on country pharmaceutical pric-
ing policies. Geneva: World Health Organization, 2013 [homepage on the
Internet]. [cited 2017 May 26]. Available from: http://www.who.int/medicines/
publications/pharm_guide_country_price_policy/en/
3. Vogler S. The impact of pharmaceutical pricing and reimbursement policies
on generics uptake: implementation of policy options on generics in 29
European countries—an overview. Generics and Biosimilars Initiative (GaBI
4. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of
5. Simoens S, De Coster S. Sustaining generic medicines markets in Europe.
6. Simoens S. Sustainable provision of generic medicines in Europe. Leuven,
7. Simoens S. A review of generic medicine pricing in Europe. Generics and Biosimi-


Annex: Generics and biosimilars policies 2016

1. Generic substitution, 2016
Definition: Practice of substituting a medicine, whether marketed under a trade name or generic name (branded or unbranded generic), with a less expensive medicine, e.g. branded or unbranded generic, often containing the same active ingredient(s). Generic substitution may be allowed (indicative generic substitution) or required (mandatory/obligatory generic substitution).

<table>
<thead>
<tr>
<th>C.</th>
<th>Generic substitution allowed (out-patients) if allowed, indicative or obligatory</th>
<th>Applicable for generics solely or also other med., e.g. parallel imported</th>
<th>Year of intro., if appl.</th>
<th>Major changes (pls. indicate year and content of change)</th>
<th>Any further comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. Biosimilar substitution (substitution of biotechnological medicines), 2016
Definition: Practice of dispensing a biosimilar medicine instead of another equivalent and interchangeable biosimilar or biotechnological originator medicine at the pharmacy level without consulting the prescriber.

<table>
<thead>
<tr>
<th>C.</th>
<th>Biosimilar substitution specific conditions for biosimilar substitution, e.g. only between biosimilars, for specific patients</th>
<th>Year of intro., if appl.</th>
<th>Legal basis for permission</th>
<th>Planned changes, discussion on changes, any further comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Definition: A switch is a decision by the treating physician to exchange one medicine for another medicine with the same therapeutic intent in patients who are undergoing treatment. Please comment whether switching to biosimilars is encouraged, and/or recommended, e.g. by authorities (at national or regional level, for instance), medical societies, in your country.

<table>
<thead>
<tr>
<th>C.</th>
<th>Switching to biosimilars is encouraged and recommended</th>
<th>Specifications of the switch related to patients (only for naïve patients, or for naïve and non-naïve patients)</th>
<th>Specifications of the switch related to medicines (switches between biosimilars, or only from originator to biosimilars)</th>
<th>Further specifications, e.g. no national recommendation</th>
<th>Any further comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. INN prescribing, 2016
Definition: Requirements for prescribers, e.g. physicians, to prescribe medicines by its INN, i.e. the active ingredient name instead of the brand name. INN prescribing may be allowed (indicative INN prescribing) or required (mandatory/obligatory INN prescribing).

<table>
<thead>
<tr>
<th>C.</th>
<th>INN prescribing (not) allowed if allowed, indicative or obligatory</th>
<th>Year of intro., if appl.</th>
<th>Major changes (pls. indicate year and content of change)</th>
<th>Any further comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. Reference price system (internal price referencing, therapeutic price referencing), 2016
Definition: The third-party payer determines a maximum price (= reference price) to be reimbursed for certain medicines. On buying a medicine for which a fixed price/amount (~ the so-called reimbursement price) has been determined, the insured person must pay
the difference between the fixed price/amount and the actual pharmacy retail price of the medicine in question, in addition to any fixed co-payment or percentage co-payment rates. The reference price is defined for all medicines in a reference group that can be designed at ATC 5 level, ATC 4 level and some other cluster. Reference price system/internal price referencing concerns referencing to medicines of your country, not to other countries.

<table>
<thead>
<tr>
<th>C.</th>
<th>RPS</th>
<th>Cluster of ref. group</th>
<th>Calculation of RP</th>
<th>Biosimilars are included in reference groups (cluster)</th>
<th>Year of intro.</th>
<th>Major changes (pls. indicate year and content of change)</th>
<th>Any further comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 6. Generic and biosimilar price links, 2016
Definition: Practice of setting the price of a generic, or biosimilar medicine, in relationship to the originator medicine price, usually at a certain percentage lower than the original medicine price. The design of the price-link policy may vary, with different percentages for the different follower products (first follower coming to the market, second follower, etc.), and in some cases the prices of originator medicines might also be part of the policy, i.e. that they will also be required to decrease.

<table>
<thead>
<tr>
<th>C.</th>
<th>Price link for generics</th>
<th>Details on generic price-link policy</th>
<th>Price link for biosim.</th>
<th>Details on biosimilar price-link policy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 7. Tendering in the outpatient sector and further pricing policies, 2016
Definition: Any formal and competitive procurement procedure through which tenders (offers) are requested, received and evaluated for the procurement of goods, works or services, and as a consequence of which an award is made to the tenderer whose tender/offer is the most advantageous. In the outpatient pharmaceutical sector, tendering is typically applied for specific medicines for which equivalents, e.g. generics, exist: public payers ask (generic) manufacturers for bids, and the best tender will be awarded a contract for a specific time.

<table>
<thead>
<tr>
<th>C.</th>
<th>Tendering in outpatients</th>
<th>Details related to generics</th>
<th>Details related to biosimilars</th>
<th>Further pricing policies related to generics or biosimilars</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 8. Specific distribution remuneration for (promoting) generics and biosimilars, 2016
Definition: For the services performed in the supply chain, wholesalers and pharmacies are remunerated through linear mark-ups, regressive margin schemes or a fee-for-service remuneration.

<table>
<thead>
<tr>
<th>C.</th>
<th>Specific rules for generics/biosim.</th>
<th>Wholesale remuneration related to generics</th>
<th>Wholesale remuneration related to biosimilars</th>
<th>Pharmacy remuneration related to generics</th>
<th>Pharmacy remuneration related to biosimilars</th>
<th>Further comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please list below any further measures in order to increase the uptake of generics, biosimilars or of low-priced medicines (demand-side measures), including information and awareness-raising activities, or any supply-side measures not mentioned above. If applicable, please add when the measures were undertaken. Please inform about discussions in your country about planned measures/developments.

<table>
<thead>
<tr>
<th>C.</th>
<th>Further measures to promote generics uptake</th>
<th>Further measures to promote biosimilars uptake</th>
<th>Ongoing discussions/plans for the future</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Disclaimer
The data contained in this document have been provided by the members of the PPRI (Pharmaceutical Pricing and Reimbursement Information) network and represent the current situation. The data do not have any legally binding value.